Ipamorelin
Growth Hormone Secretagogue - Selective GH secretagogue studied for receptor-selective GH release.
Ipamorelin is a selective growth-hormone secretagogue and ghrelin-receptor agonist, studied for its reported ability to stimulate GH release without significantly affecting cortisol or prolactin.
Ipamorelin is prized in research for its selectivity - it stimulates GH release through the ghrelin receptor with minimal effect on cortisol or prolactin, giving a cleaner readout than earlier secretagogues. It is a common partner for GHRH analogs in combination GH studies.
Ipamorelin specifications
- Sequence
- Synthetic pentapeptide
- Presentation
- Lyophilised powder
- Documented purity
- 99.73% by HPLC
- Available sizes
- 10mg ($80)
- Archived COA lots
- 4
- Intended use
- Laboratory research use only. Not for human or veterinary use.
Studied pathways
- Ghrelin receptor - Selective secretagogue studied for GH release with minimal off-target hormone activity.
Reported mechanisms in the literature
- Ghrelin receptor - A selective growth-hormone secretagogue and ghrelin-receptor agonist studied for GH release with minimal off-target effect on cortisol or prolactin. (Raun et al.)
Ipamorelin frequently asked questions
What is Ipamorelin?
A selective growth-hormone secretagogue and ghrelin-receptor agonist, studied for stimulating GH release without significantly affecting cortisol or prolactin.
Is it approved for human use?
No. It is a research material only, with preclinical data. It is not a medicine or supplement.
What is it researched for?
Selective GH secretagogue activity via the ghrelin receptor in animal models.
Documented to 99.73% purity by HPLC · third-party COA every lot · from $80 · For laboratory research use only.
Related Growth Hormone compounds
- Tesamorelin - GHRH analog studied for growth-hormone-axis research.
- CJC-1295 - GHRH analog studied for sustained GH signalling.
- CJC-1295 DAC - Long-acting GHRH analog with drug-affinity complex.